Drugs / GW869682
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00494767 | Sep 2006 → Jun 2007 | obesity disorder, type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00291356 | Jan → May 2006 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00297180 | Jan → Sep 2006 | obesity disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW869682 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00494767 ↗ |
| Action | Inhibit | “GW869682, an SGLT2 Inhibitor” NCT00297180 ↗ |
| Route | Oral | “GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth” NCT00291356 ↗ |